David Dai

Stock Analyst at UBS

(0)
# 4868
Out of 5,240 analysts
21
Total ratings
12.50%
Success rate
-28.05%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
Immunocore Hldgs
Initiates Coverage On: Sell
24
28.5 -15.79% 1 Oct 24, 2024
Nuvalent
Initiates Coverage On: Neutral
100
72.37 38.18% 1 Oct 24, 2024
Blueprint Medicines
Initiates Coverage On: Neutral
88
102.53 -14.17% 1 Oct 24, 2024
Perspective Therapeu...
Initiates Coverage On: Buy
20
3.23 519.2% 1 Oct 24, 2024
Nurix Therapeutics
Initiates Coverage On: Buy
35
18.56 88.58% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
39 84.62% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
27
7.25 272.41% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
69
45.33 52.22% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
22.73 119.97% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
17
5.89 188.62% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
30
10.01 199.7% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
27.91 114.98% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
37
12.61 193.42% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
0.91 2976.92% 1 Mar 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
12.85 211.28% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
3.04 1215.79% 1 Feb 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
2.21 2162.44% 1 Nov 18, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
41 52
34.74 49.68% 1 Mar 17, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
41
n/a n/a 1 Apr 25, 2017